Last Update 30 Jul 26
Fair value Increased 2.51%GEHC: AI Imaging And Diagnostics Adoption Will Drive 2026 Stock Repricing
Analysts have raised the central price target on GE HealthCare Technologies by $2 to $81.72, citing updated views on revenue growth, margins, and risk following a series of recent target changes across Wall Street.
Analyst Commentary
Recent research updates on GE HealthCare Technologies show a mix of optimism and caution, with price targets spread across the high US$60s to low US$80s and ratings clustered around Neutral, Market Perform, Outperform and Buy. For you as an investor, the key themes are how confident analysts feel about the company’s execution, long term growth potential, and whether the current valuation already reflects the known risks.
Bullish Takeaways
- Bullish analysts point to GE HealthCare’s product portfolio and specific platforms such as Flyrcado and Photonova Spectra as meaningful growth drivers, arguing that these assets can support a premium against peers if execution stays on track.
- Some research points to increased research and development investment and stronger commercial execution since the 2023 spin from General Electric. Supporters see this as a sign that GE HealthCare can convert its backlog into future orders and revenue growth.
- Several firms that maintain Buy or Outperform ratings see the current share price as offering an attractive risk and reward setup, with order momentum and a strong backlog seen as supportive of the long term growth case.
- Bullish analysts also highlight recent quarterly results as evidence that GE HealthCare can operate through a challenging macro backdrop, retain or win share in key markets, and potentially justify higher earnings estimates over time.
Bearish Takeaways
- Bearish analysts and those with Neutral or Market Perform ratings see the risk and reward as more balanced at current levels. They highlight that the stock is in what they describe as “show me” territory after macro driven guidance cuts, which puts more pressure on execution.
- Some research flags concerns around new product execution, China exposure, and inflationary pressures. Even where ratings have shifted from more negative to Neutral, there is still skepticism about upside catalysts in the near term.
- Cautious analysts note that sector level factors in MedTech and healthcare equipment, including prior underperformance and recent stabilization, mean that earnings reports may act more as sentiment checks rather than clear re-rating triggers.
- There are also forecasts that sit below management’s mid term guidance. This gap reflects a view that current expectations may be too optimistic unless GE HealthCare delivers consistent execution on its backlog and product launches.
What’s in the News for GE HealthCare Technologies
- GE HealthCare and Catholic Health agreed a 10 year Care Alliance valued at about US$500m to modernize imaging, precision diagnostics and AI enabled technology across more than 40 sites, covering over 1,300 pieces of equipment plus software, cloud and long term service support. Sources: company release and Catholic Health announcement.
- GE HealthCare reported preliminary Q2 2026 results that were above prior revenue and earnings expectations and reaffirmed full year 2026 guidance, alongside a planned CFO transition as Jay Saccaro prepares to leave and Controller and Chief Accounting Officer George Newcomb steps in as interim CFO. Sources: company guidance update and executive change filings.
- The company completed a further US$200m share repurchase in Q2 2026, bringing total buybacks under the April 2025 program to US$500m and 7,494,146 shares, which is 1.64% of shares outstanding. Source: buyback tranche update.
- GE HealthCare is conducting a comprehensive review of its Patient Care Solutions business after continued operational and supply chain challenges. Options under review range from retaining the unit to a potential sale or other transactions. Source: company strategic review announcement.
- On the product side, GE HealthCare continues to develop its AI and imaging portfolio, including the launch of MIM Anyware for remote imaging data access and FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0 auto contouring software in radiation oncology, as well as ongoing collaborations with Mayo Clinic and others in theranostics and MR research. Sources: company product and research announcements.
Valuation Changes for GE HealthCare Technologies
- Fair Value has risen slightly, with the central estimate moving from $79.72 to $81.72 per share.
- Discount Rate has fallen modestly from 8.15% to 7.93%, which implies a lower required return in the model being used.
- Revenue Growth is now set at 4.56% compared with the prior 4.53%. This reflects a very small adjustment to expected top line expansion for GE HealthCare Technologies in dollar terms.
- Net Profit Margin has been nudged higher from 10.71% to 10.84%, indicating a slightly stronger earnings profile in the updated assumptions.
- Future P/E has been trimmed from 17.65x to 17.04x. This suggests a somewhat lower valuation multiple is being applied to forward earnings in the model.
0 viewsusers have viewed this narrative update
Key Takeaways
- Expansion through partnerships and growing market share is likely to drive revenue growth and enhance revenue stability.
- New technologies and acquisitions in diagnostics are positioned to significantly boost future revenue and earnings.
- Tariffs and regulatory uncertainties may hinder earnings and revenue growth, with competitive pressures impacting market share and cash flow constraints limiting financial flexibility.
Catalysts
About GE HealthCare Technologies- Engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally.
- Expansion of market presence, driven by new partnerships with top IDNs and increased market share, is likely to boost future revenue growth.
- Ongoing mitigation strategies for tariff impacts, including supply chain optimization and local manufacturing shifts, are expected to enhance net margins and earnings.
- The pipeline of new high-impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins.
- The focus on expanding recurring revenue, particularly in areas like digital solutions and advanced visualization, is expected to contribute positively to revenue stability and net margins.
- The launch of Flyrcado and recent acquisition activities are aimed at bolstering revenue streams in pharmaceutical diagnostics, which may contribute to overall revenue and earnings growth.
GE HealthCare Technologies Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming GE HealthCare Technologies's revenue will grow by 4.6% annually over the next 3 years.
- Analysts assume that profit margins will increase from 9.3% today to 10.8% in 3 years time.
- Analysts expect earnings to reach $2.6 billion (and earnings per share of $5.82) by about July 2029, up from $2.0 billion today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.1x on those 2029 earnings, up from 15.9x today. This future PE is lower than the current PE for the US Medical Equipment industry at 29.3x.
- Analysts expect the number of shares outstanding to decline by 1.07% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.93%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The impact of tariffs, particularly between the U.S. and China, poses significant risk, with $0.85 impacting adjusted EPS, which could hinder margins and earnings.
- The uncertainty and potential regulatory changes in China, including antidumping investigations and rare earth export limitations, may impact revenue growth from this important market.
- The company faces challenges from competitor advancements in their product pipeline, which may put pressure on maintaining or increasing market share, affecting future revenues.
- Free cash flow has been reduced largely due to tariff impacts and inventory build, which may constrain operational liquidity and financial flexibility.
- While there is confidence in market demand, changes in the macroeconomic landscape, including global trade policies and foreign exchange volatility, can introduce significant earnings and margin risks.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $81.72 for GE HealthCare Technologies based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $96.0, and the most bearish reporting a price target of just $67.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $24.3 billion, earnings will come to $2.6 billion, and it would be trading on a PE ratio of 17.1x, assuming you use a discount rate of 7.9%.
- Given the current share price of $69.97, the analyst price target of $81.72 is 14.4% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on GE HealthCare Technologies?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
US$98
FV
28.6% undervalued intrinsic discount5.78%
Revenue growth p.a.
16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$65
FV
7.6% overvalued intrinsic discount4.14%
Revenue growth p.a.
19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative